U.S. Markets closed

Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day

LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce Steel, Equillium’s president and chief business officer, will present at the Solebury Trout Class of 2018 Biotech IPO Investor Day on Friday, April 26, 2019. 

Date:               Friday, April 26, 2019
Time:               2:00 PM Eastern Time | 11:00 AM Pacific Time
Location:        Davis Polk Offices, 450 Lexington Avenue, New York, NY

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.

About Equillium
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.

Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the activity and trafficking of Teff cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to EQ001 through an exclusive partnership with Biocon Limited. Equillium believes that EQ001 has the potential to be a best-in-class disease modifying therapeutic and is advancing EQ001 into clinical development in multiple immuno-inflammatory indications with high unmet medical need. For more information, visit www.equilliumbio.com.

Investor Contact
+1-858-412-5302
ir@equilliumbio.com

Media Contact
Heidi Chokeir, Ph.D.
Canale Communications
+1-619-203-5391
heidi@canalecomm.com